The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the
Sebastian M Fiebiger1, Helena Bros, Thomas Grobosch
1Institute for Medical Immunology, Charité-Universitätmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Abstract:
Oxidative stress and mitochondrial dysfunction appear to contribute to neurodegenerative processes during multiple sclerosis (MS). Thus, antioxidants may represent a therapeutic option for MS. The antioxidant idebenone was proven to be beneficial in Friedreich's ataxia and Leber's hereditary optic neuropathy, two disorders caused by mitochondrial alterations. Here we showed that idebenone protected neuronal HT22 cells from glutamate-induced death in vitro. However, in experimental autoimmune encephalomyelitis, idebenone failed to affect disease incidence or onset when applied preventively, or to reduce disease severity when applied therapeutically. Histopathological examination of CNS from idebenone treated mice showed no improvement in inflammation, demyelination, or axonal damage. Thus, we hypothesize that idebenone treatment will likely not benefit patients with MS.
Insights
Idebenone protected neurons in lab tests but failed to improve multiple sclerosis (MS) in animal models. This suggests idebenone may not be an effective treatment for MS patients.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Oxidative stress and mitochondrial dysfunction are implicated in neurodegeneration in multiple sclerosis (MS).
- Antioxidants are being explored as potential therapeutics for MS.
- Idebenone has shown benefits in other mitochondrial disorders.
Purpose of the Study:
- To investigate the therapeutic potential of idebenone in a mouse model of multiple sclerosis.
- To evaluate idebenone's effects on neuronal protection and disease progression in experimental autoimmune encephalomyelitis (EAE).
Main Methods:
- In vitro testing of idebenone on glutamate-induced neuronal death.
- Administration of idebenone preventively and therapeutically in EAE mice.
- Histopathological analysis of the central nervous system (CNS) in treated mice.
Main Results:
- Idebenone demonstrated neuroprotective effects on HT22 cells in vitro.
- Idebenone did not alter disease incidence, onset, or severity in EAE mice.
- No improvements in CNS inflammation, demyelination, or axonal damage were observed with idebenone treatment.
Conclusions:
- Despite in vitro efficacy, idebenone failed to demonstrate therapeutic benefits in an animal model of MS.
- Idebenone treatment is unlikely to be beneficial for patients with multiple sclerosis.
More Related Videos
05:44Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019